Goldman Sachs initiated coverage of HealthEquity (HQY) with a Neutral rating and $108 price target The firm says its thesis on HealthEquity is balanced by a constructive view on the company’s forward earnings outlook and a clear path to achieving long-term earnings targets with what it sees as a balanced risk/reward based on valuation.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks